Effects of blood collection conditions on ovarian cancer serum markers

PLoS ONE

Volumn 2, Issue 12, 2007, Pages

  Thorpe, Jason D ^a   Duan, Xiaobo ^c   Forrest, Robin ^a   Lowe, Kimberly ^a   Brown, Lauren ^a   Segal, Elliot ^b   Nelson, Brad ^c   Anderson, Garnet L ^a   McIntosh, Martin ^a   Urban, Nicole ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b Onco Detectors International LLC   (United States)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; MACROPHAGE MIGRATION INHIBITION FACTOR; PROLACTIN; ISOMERASE; MIF PROTEIN, HUMAN; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; BLOOD STORAGE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HORMONE BLOOD LEVEL; HUMAN; OVARY CANCER; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PROTEIN CONTENT; ROC CURVE; SAMPLING ERROR; BLOOD; CASE CONTROL STUDY; LABORATORY DIAGNOSIS; OVARY TUMOR;

CA-125 ANTIGEN; CASE-CONTROL STUDIES; FEMALE; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; MACROPHAGE MIGRATION-INHIBITORY FACTORS; OVARIAN NEOPLASMS; PROLACTIN; ROC CURVE; SPECIMEN HANDLING; TUMOR MARKERS, BIOLOGICAL;

EID: 44249111197     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0001281     Document Type: Article

References (34)

1. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, et al. (2001) Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 93: 1054-1061.
2. Pepe M (2005) Evaluating technologies for classification and prediction in medicine. Statistics in Medicine 24: 3687-3696.
3. Rosenthal AN, Menon U, Jacobs IJ (2006) Screening for ovarian cancer. Clin Obstet Gynecol 49: 433-447.
4. Pauler DK, Menon U, McIntosh M, Symecko HL, Skates SJ, et al. (2001) Factors Influencing Serum CA125II Levels in Healthy Postmenopausal Women. Cancer Epidemiol Biomarkers Prev 10: 489-493.
5. Skates SJ, Menon U, MacDonald N, Rosenthal AN, Oram DH, et al. (2003) Calculation of the Risk of Ovarian Cancer From Serial CA-125 Values for Preclinical Detection in Postmenopausal Women. J Clin Oncol 21: 206s-210.
6. Bjorge T, Lie A, Hovig E, Gislefoss R, Hansen S, et al. (2004) BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study. Br J Cancer 91: 1829-1834.
7. Daoud E, Bodor G (1991) CA-125 concentrations in malignant and nonmalignant disease. Clin Chem 37: 1968-1974.
8. Rustin GJ, Nelstrop AE, McClean P, Brady MF, McGuire WP, et al. (1996) Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 14: 1545-1551.
9. Niloff JM, Knapp RC, Lavin PT, Malkasian GD, Berek JS, et al. (1986) The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer. Am J Obstet Gynecol 155: 56-60.
10. Gubbels JA, Belisle J, Onda M, Rancourt C, Migneault M, et al. (2006) Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer 5: 50.
11. Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, et al. (2004) Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem 279: 9190-9198.
12. Mor G, Visintin I, Lai Y, Zhao H, Schwartz P, et al. (2005) Serum protein markers for early detection of ovarian cancer. Proc, Natl Acad Sci U S A 102: 7677-7682.
13. Agarwal R, Whang DH, Alvero AB, Visintin I, Lai Y, et al. (2007) Macrophage migration inhibitory factor expression in ovarian cancer. Am J Obstet Gynecol 196: 348 e341-345.
14. Bucala R, Donnelly SC (2007) Macrophage migration inhibitory factor: a probable link between inflammation and cancer. Immunity 26: 281-285.
15. Lolis E (2001) Glucocorticoid counter regulation: macrophage migration inhibitory factor as a target for drug discovery. Curr Opin Pharmacol 1: 662-668.
16. Mitchell RA, Liao H, Chesney J, Fingerle-Rowson G, Baugh J, et al. (2002) Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc Natl Acad Sci U S A 99: 345-350.
17. Hudson JD, Shoaibi MA, Maestro R, Carnero A, Hannon GJ, et al. (1999) A proinflammatory cytokine inhibits p53 tumor suppressor activity. Journal Of Experimental Medicine 190: 1375-1382.
18. Chesney J, Metz C, Bacher M, Peng T, Meinhardt A, et al. (1999) An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma. Mol Med 5: 181-191.
19. Hira E, Ono T, Dhar DK, El-Assal ON, Hishikawa Y, et al. (2005) Overexpression of macrophage migration inhibitory factor induces angiogenesis and deteriorates prognosis after radical resection for hepatocellular carcinoma. Cancer 103: 588-598.
20. Freeman ME, Kanyicska B, Lerant A, Nagy G (2000) Peolactin: structure, function, and regulation of secretion. Physiol Rev 80: 1523-1631.
21. Mujagic Z, Mujagic H (2004) Importance of serum prolactin determination in metastatic breast cancer patients. Croat Med J 45: 176-180.
22. Mujagic Z, Mujagic H, Prnjavorac B (2005) Circulating levels of prolactin in breast cancer patients. Med Arh 59: 33-35.
23. Tworoger SS, Eliassen AH, Rosner B, Sluss P, Hankinson SE (2004) Plasma Prolactin Concentrations and Risk of Postmenopausal Breast Cancer. Cancer Res 64: 6814-6819.
24. Nevalainen MT, Valve EM, Ingleton PM, Nurmi M, Martikainen PM, et al. (1997) Prolactin and Prolactin Receptors Are Expressed and Functioning in Human Prostate. J Clin Invest 99: 618-627.
25. Indinnimeo M, Gicchini C, Memeo L, Stazi A, Ghini C, et al. (2001) Plasma and tissue prolactin detection in colon carcinoma. Oncol Rep 8, 1351-1353.
26. Andersen MR, Smith R, Meischke H, Bowen D, Urban N (2003) Breast cancer worry and mammography use by women with and without a family history in a population-based sample. Cancer Epidemiology, Biomarkers & Prevention 12: 314-320.
27. Ho D, Imai K, King G, Stuart E (2006) MatchIt: Nonparametric Preprocessing for Parametric Casual Inference. R package version 2.2-7 ed.
28. Scholler N, Crawford M, Sato A, Drescher CW, O'Briant KC, et al. (2006) Bead-Based ELISA for Validation of Ovarian Cancer Early Detection Markers. Clin Cancer Res 12: 2117-2124.
29. Sing T, Sander O, Beerenwinkel N, Lengauer T (2005) ROCR: Visualizing die performance of scoring classifiers. R package version 1.0-1, ed.
30. Metz CE, Herman BA, Roe CA (1998) Statistical comparison of two ROC-curve estimates obtained from partially-paired datasets. Med Decis Making 18: 110-121.
31. Metz C (1998) ROCKIT 1.1B2. Beta Version ed. Chicago: Department of Radiology, University of Chicago.
32. Team RDC (2006) R: A language and environment for statistical computing.
33. Hagen C, Brandt MR, Kehler H (1980) Prolactin, LH, FSH, GH and cordsol response to surgery and the effect of epidural analgesia. Acta Endocrinol (Copenh) 94: 151-154.
34. Donnerer J, Lembeck F (1990) Different control of the adrenocorticotropin-corticosterone response and of prolactin secretion during cold stress, anesthesia, surgery, and nicotine injection in the rat: involvement of capsaicin-sensitive sensory neurons. Endocrinology 126: 921-926.